X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs STERLING BIOTECH - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB STERLING BIOTECH DR. REDDYS LAB/
STERLING BIOTECH
 
P/E (TTM) x 41.8 -0.6 - View Chart
P/BV x 3.2 0.0 13,730.7% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 DR. REDDYS LAB   STERLING BIOTECH
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-17
STERLING BIOTECH
Dec-13
DR. REDDYS LAB/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs3,39711 32,349.5%   
Low Rs2,5603 75,294.1%   
Sales per share (Unadj.) Rs856.526.8 3,195.2%  
Earnings per share (Unadj.) Rs78.0-15.0 -521.2%  
Cash flow per share (Unadj.) Rs139.9-5.5 -2,561.0%  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs739.854.9 1,348.1%  
Shares outstanding (eoy) m165.74267.87 61.9%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x3.50.3 1,341.2%   
Avg P/E ratio x38.2-0.5 -8,221.7%  
P/CF ratio (eoy) x21.3-1.3 -1,673.3%  
Price / Book Value ratio x4.00.1 3,178.9%  
Dividend payout %25.70-   
Avg Mkt Cap Rs m493,6321,862 26,515.1%   
No. of employees `00022.71.4 1,675.1%   
Total wages/salary Rs m31,068547 5,681.8%   
Avg. sales/employee Rs Th6,259.05,303.3 118.0%   
Avg. wages/employee Rs Th1,369.8403.8 339.2%   
Avg. net profit/employee Rs Th569.7-2,959.0 -19.3%   
INCOME DATA
Net Sales Rs m141,9617,181 1,977.0%  
Other income Rs m1,71543 4,025.8%   
Total revenues Rs m143,6767,223 1,989.1%   
Gross profit Rs m24,722947 2,610.8%  
Depreciation Rs m10,2662,543 403.7%   
Interest Rs m6344,377 14.5%   
Profit before tax Rs m15,537-5,931 -262.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m3490-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,965-1,924 -154.1%   
Profit after tax Rs m12,921-4,007 -322.5%  
Gross profit margin %17.413.2 132.1%  
Effective tax rate %19.132.4 58.8%   
Net profit margin %9.1-55.8 -16.3%  
BALANCE SHEET DATA
Current assets Rs m96,83714,335 675.5%   
Current liabilities Rs m84,19949,809 169.0%   
Net working cap to sales %8.9-494.0 -1.8%  
Current ratio x1.20.3 399.6%  
Inventory Days Days73403 18.2%  
Debtors Days Days98171 57.2%  
Net fixed assets Rs m102,55255,432 185.0%   
Share capital Rs m829268 309.4%   
"Free" reserves Rs m121,79213,935 874.0%   
Net worth Rs m122,62114,701 834.1%   
Long term debt Rs m5,4499,478 57.5%   
Total assets Rs m218,16573,988 294.9%  
Interest coverage x25.5-0.4 -7,185.7%   
Debt to equity ratio x00.6 6.9%  
Sales to assets ratio x0.70.1 670.5%   
Return on assets %6.20.5 1,240.4%  
Return on equity %10.5-27.3 -38.7%  
Return on capital %12.9-6.4 -200.7%  
Exports to sales %54.625.9 210.8%   
Imports to sales %9.40.2 5,503.5%   
Exports (fob) Rs m77,5201,860 4,168.2%   
Imports (cif) Rs m13,27412 108,803.3%   
Fx inflow Rs m81,6701,860 4,391.3%   
Fx outflow Rs m26,35525 105,885.9%   
Net fx Rs m55,3151,835 3,014.6%   
CASH FLOW
From Operations Rs m21,4441,719 1,247.7%  
From Investments Rs m-18,404-3,148 584.6%  
From Financial Activity Rs m-3,6921,426 -258.9%  
Net Cashflow Rs m-1,144-3 33,647.1%  

Share Holding

Indian Promoters % 25.5 33.9 75.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 0.0 -  
FIIs % 35.3 9.9 356.6%  
ADR/GDR % 18.5 16.9 109.5%  
Free float % 15.3 39.3 38.9%  
Shareholders   75,885 21,482 353.2%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   NOVARTIS  TORRENT PHARMA  FRESENIUS KABI ONCO.  CIPLA  ASTRAZENECA PHARMA  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Rising Oil Prices; RBI Minutes and Top Stocks in Action Today(Pre-Open)

Indian share markets surged on Wednesday, snapping a two-day losing streak led by gains Reliance Industries and bank stocks.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Jun 20, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - GLENMARK PHARMA COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS